## Table of Contents

### BREAKING ADVANCES

2961  
Highlights from Recent Cancer Literature

### REVIEWS

2963  
Maintaining Tumor Heterogeneity in Patient-Derived Tumor Xenografts  
John W. Cassidy, Carlos Caldas, and Alejandra Bruna

2969  
Plasminogen Activator Inhibitor-1 in Cancer: Rationale and Insight for Future Therapeutic Testing  
Veronica R. Placencio and Yves A. DeClerck

### INTEGRATED SYSTEMS AND TECHNOLOGIES

2975  
Neuroendocrine Transdifferentiation in Human Prostate Cancer Cells: An Integrated Approach  
Marianna Cerasuolo, Debora Paris, Fabio A. Iannotti, Dominique Melck, Roberta Verde, Enrico Mazzarella, Andrea Motta, and Alessia Ligresti

2987  
Identification of Prognostic Groups in High-Grade Serous Ovarian Cancer Treated with Platinum–Taxane Chemotherapy  
Ping Chen, Kaisa Huhtinen, Katja Kaipio, Piia Mikkonen, Viljami Aittomäki, Rony Lindell, Johanna Hynninen, Annika Auronen, Seija Grénman, Rainer Lehtonen, Olli Carpién, and Sampsa Hautaniemi

2999  
**IDH1** Mutation Induces Reprogramming of Pyruvate Metabolism  

### MICROENVIRONMENT AND IMMUNOLOGY

3010  
A Systematic Approach to Defining the microRNA Landscape in Metastasis  

3020  
Novel Cell-Penetrating Peptide-Based Vaccine Induces Robust CD4^+^ and CD8^+^ T Cell-Mediated Antitumor Immunity  
Madiha Derouazi, Wilma Di Berardino-Besson, Elodie Belnoue, Sabine Hoepner, Romy Walther, Mahdia Benkhoucha, Patrick Teta, Yannick Dufour, Céline Yacoub Maroun, Andres M. Salazar, Denis Martinvalet, Pierre-Yves Dietrich, and Paul R. Walker

3032  
Oncogenic Transformation Can orchestrate Immune Evasion and Inflammation in Human Mesenchymal Stem Cells Independently of Extrinsic Immune-Selective Pressure  
Alex Miranda, Juan M. Funes, Nilda Sánchez, Celia M. Limia, Mónica Mesa, Sergio A. Quezada, Rolando Pérez, and Joel de León

3043  
Neuroblastoma Arginase Activity Creates an Immunosuppressive Microenvironment That Impairs Autologous and Engineered Immunity  
Francis Mussai, Sharon Egan, Stuart Hunter, Hannah Webber, Jonathan Fisher, Rachel Wheat, Carmel McConville, Yordan Shirkov, Kate Wheeler, Gavin Bendle, Kevin Petrie, John Anderson, Louis Chesler, and Carmela De Santo
Tristetraprolin Limits Inflammatory Cytokine Production in Tumor-Associated Macrophages in an mRNA Decay–Independent Manner
Franz Kratochvill, Nina Grat, Joseph E. Qualil, Lee-Ann Van De Velde, Hongbo Chi, Pavel Kovarik, and Peter J. Murray
Précis: Manipulation of a p38 kinase-related signaling axis in macrophages appears to strongly affect the growth of solid tumors, suggesting a new strategy to reprogram inflammation in tumor microenvironments.

Cytomegalovirus Immediate-Early Proteins Promote Stemness Properties in Glioblastoma
Liliana Soroceanu, Lisa Matlaf, Sabeena Khan, Armin Akhavan, Eric Singer, Vladimir Bezrookove, Stacy Decker, Salerna Ghanny, Piotr Hadaczek, Henrik Bengtsson, John Ohlfest, Maria-Gloria Luciani-Torres, Lualhati Harkins, Arie Perry, Hong Guo, Patricia Soteropoulos, and Charles S. Cobbs
Précis: This study unveils a novel paradigm in viral oncogenesis, exposing the role of human cytomegalovirus in driving the growth of cancer stem cells in glioblastoma.

EGF Receptor Promotes Prostate Cancer Bone Metastasis by Downregulating miR-1 and Activating TWIST1
Yung-Sheng Chang, Wei-Yu Chen, Juan Juan Yin, Heather Sheppard-Tillman, Jiaoti Huang, and Yen-Nien Liu
Précis: The findings of this study raise the interesting idea that miRNA expression might be directly targeted by nuclear growth factor receptor isoforms, with relevance for the coordinated progression of malignancy.

KIAA1324 Suppresses Gastric Cancer Progression by Inhibiting the Oncoprotein GRP78
Jin Muk Kang, Sujein Park, Staci Jakyong Kim, Hyojung Kim, Bona Lee, Junil Kim, Jinah Park, Shin Tae Kim, Han-Kwang Yang, Woo Ho Kim, and Seong-Jin Kim
Précis: These findings provide evidence of a novel mechanism of gastric carcinogenesis and also suggest a novel potential biomarker and therapeutic target for gastric cancer.

Interleukin-6 Stimulates Defective Angiogenesis
Ganga Gopinathan, Carla Milagre, Oliver M.T. Pearce, Louise E. Reynolds, Kairbaan Hodivala-Dille, David A. Leinster, Haihong Zhong, Robert E. Hollingsworth, Richard Thompson, James R. Whiteford, and Frances Balkwill
Précis: These findings have important implications for understanding abnormal angiogenic processes in cancer, as well as their connection to immune escape and the use of VEGF or IL6 targeting therapies in cancer patients.

Implication of a Chromosome 15q15.2 Locus in Regulating UBR1 and Predisposing Smokers to MGMT Methylation in Lung
Précis: Genetic polymorphisms that affect DNA methylation of the DNA repair gene MGMT have strong clinical relevance in smokers, not only for cancer risk assessment but also for stratification of lung cancer patients for alkylating agent chemotherapy.

Erlotinib Pretreatment Improves Photodynamic Therapy of Non–Small Cell Lung Carcinoma Xenografts via Multiple Mechanisms
Shannon M. Gallagher-Colombo, Joann Miller, Keith A. Cengel, Mary E. Putt, Sergei A. Vinogradov, and Theresa M. Busch
Précis: These findings offer a strong impetus to incorporate the EGFR inhibitor erlotinib into clinical trials of photodynamic therapy, based on understanding drug mechanisms that rationalize its combination with other cytotoxic therapies.
TUMOR AND STEM CELL BIOLOGY

3127 Minor Changes in Expression of the Mismatch Repair Protein MSH2 Exert a Major Impact on Glioblastoma Response to Temozolomide
José E. McFaline-Figueroa, Christian J. Braun, Monica Stanciu, Zachary D. Nagel, Patrizia Mazzucato, Dewaker Sangaraju, Edvinas Cerniauskas, Kelly Barford, Amanda Vargas, Yinlin Chen, Natalia Tretjakova, Jacqueline A. Lees, Michael T. Hemann, Forest M. White, and Leona D. Samson
Précis: Modest decreases in DNA mismatch repair factor MSH2 can dramatically alter chemosensitivity to a drug used commonly to treat aggressive cancers, with little effect on the mismatch repair itself, suggesting that subtle mismatch repair changes mediating drug resistance may be more prevalent than appreciated.

3139 Identification of Oncogenic and Drug-Sensitizing Mutations in the Extracellular Domain of FGFR2
Précis: Based on other advances in targeting FGF receptors in cancer, the novel mutations identified in this study in the extracellular domain of the FGF receptor FGFR2 could offer therapeutic targets in a variety of solid tumors.

3147 Improving Drug Penetrability with iRGD Leverages the Therapeutic Response to Sorafenib and Doxorubicin in Hepatocellular Carcinoma
Précis: These findings establish a clinically tractable method to safely widen the therapeutic window for chemotherapy in patients with liver cancer, along with a noninvasive method to identify candidate subjects, offering immediate translational impact for evaluation in human trials.

3155 CASC15-S Is a Tumor Suppressor IncRNA at the 6p22 Neuroblastoma Susceptibility Locus
Précis: This unbiased genetic association study identifies the involvement of a long noncoding RNA in initiating pediatric neuroblastoma, helping explain the low somatic mutation rates in protein coding genes observed in this lethal malignancy and suggesting new directions for therapeutic intervention.

3167 TP53 Silencing Bypasses Growth Arrest of BRAFV600E-Induced Lung Tumor Cells in a Two-Switch Model of Lung Tumorigenesis
Anny Shai, David Dankort, Joseph Juan, Shon Green, and Martin McMahon
Précis: This study describes new mouse models for temporal dissociation of genetic events in lung carcinogenesis and establishes a core role for the p53 pathway in restricting lung cancer development.

3181 Amplification of Long Noncoding RNA ZFAS1 Promotes Metastasis in Hepatocellular Carcinoma
Tao Li, Junjie Xie, Chuan Shen, Dongfeng Cheng, Yuan Shi, Zhichong Wu, Xiaoxing Deng, Hao Chen, Baiyong Shen, Chenghong Peng, Hongwei Li, Qian Zhan, and Zhecheng Zhu
Précis: These findings illuminate the oncogenic function of a noncoding RNA that acts by opposing tumor-suppressive effects of miR-150, suggesting utility as a prognostic biomarker or target for clinical management of HCC.
ABOUT THE COVER

The immunofluorescence image is of an aortic ring treated with IL6 stained for vessels (green), pericytes (red), and cell nuclei (blue). Here, it is shown that IL6 stimulates angiogenesis with defective pericyte coverage. Treatment of peritoneal xenografts of ovarian cancer with an anti-IL6 antibody restored pericyte coverage of the tumor blood vessels. The authors' findings have implications for the use of cancer therapies that target IL6 and for understanding abnormal angiogenesis in cancers, chronic inflammatory disease, and stroke. For details, see article by Gopinathan and colleagues on page 3098.